SilcsBio Joins with NIST and Pharma Partner In Validating SILCS Technology for Biologics Formulation
FOR IMMEDIATE RELEASE: SilcsBio Joins with NIST and Pharma Partner In Validating SILCS Technology for Biologics Formulation Scientific collaboration demonstrates effective computational method for stabilizing biologic therapeutics such as antibodies December 16, 2020, Baltimore, MD – SilcsBio, LLC, a technology company that develops and markets software and services for structure-based drug design, today announced members […]
SilcsBio and Dalriada Drug Discovery Launch Partnership to Create a Rapid Drug Discovery Service Suite
SilcsBio and Dalriada to tap areas of expertise in drug design and development to accelerate clients’ programs in development of therapeutic treatments against diseases with unmet needs, initiated with COVID-19 FOR IMMEDIATE RELEASE: June 11, 2020, Baltimore, MD and Toronto, ON – SilcsBio, a technology company that develops innovative software and provides services for structure-based […]
GEn1E Lifesciences, a Y Combinator-Backed Company, Granted Exclusive License for University of Maryland, Baltimore Drug Portfolio Compound
GEn1E Lifesciences, a Y Combinator-Backed Company, Granted Exclusive License for University of Maryland, Baltimore Drug Portfolio Compound Tuesday, December 3, 2019 PALO ALTO, Calif. and BALTIMORE, Dec. 3, 2019 /PRNewswire/ — GEn1E Lifesciences Inc., a Y Combinator-backed biotech startup focused on curing inflammatory and age-related diseases, announced today that it has acquired an exclusive, worldwide and […]
New SILCS-MC Study Demonstrates Improved Performance with Machine Learning Optimization
New SILCS-MC Study Demonstrates Improved Performance with Machine Learning Optimization May 16, 2019, Baltimore, MD – SilcsBio, a company that develops commercial software and related services for structure-based drug design, today announced that established Site-identification by ligand competitive saturation-Monte Carlo (SILCS-MC) approaches were applied to seven protein targets and 551 ligands, correctly predicting […]
SilcsBio, LLC Announces Release of CGenFF 2.3.0
Baltimore, MD, 26 April, 2019 In ongoing efforts to improve the coverage of the CGenFF program, version 2.3.0 of the CGenFF program improves support for a variety of molecules via explicit parametrization of the molecules outlined below and features improvements for halogen-protein interactions. Molecules explicitly parametrized The functional groups in these molecules were previously accessible […]
Sygnature Discovery announces collaboration with software firm SilcsBio
SilcsBio, LLC Receives NIH Funding to Expand Offerings in Biologics
FOR IMMEDIATE RELEASE: April 11, 2019 Ken Malone SilcsBio, LLC 410.929.2305 Ken.Malone@silcsbio.com SilcsBio, LLC Receives NIH Funding to Expand Offerings in Biologics Baltimore, Maryland: SilcsBio, LLC announced today a $225,000 award from the National Institutes of Health to expand on its broadly used software, SILCS, to enable its use with biological therapeutics, especially for […]